Kamalpreet Singh, MD
Endocrinology, Diabetes & Metabolism · Round Rock, TXNPI 1750543435
Payments from drug & device makers
Across 177 payments — averaging $1870.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$315K
- Novartis$11K
- Eli Lilly$3K
- Novo Nordisk$657
- IBSA Pharma Inc.$533
- Lilly USA, LLC$142
- plus $728 from 17 others
Across 3 payments — averaging $9210.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$28K
What the payments were for
- Consulting fees$50023%
- Food & beverage$1,63577%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 53 | $315,249 |
| Novartis | 4 | $10,559 |
| Eli Lilly | 2 | $3,282 |
| Novo Nordisk | 72 | $657 |
| IBSA Pharma Inc. | 3 | $533 |
| Lilly USA, LLC | 8 | $142 |
| Amgen | 6 | $102 |
| BETA Bionics, Inc. | 4 | $90 |
| Abbott | 4 | $73 |
| Tandem Diabetes Care, Inc. | 4 | $55 |
| Ascendis Pharma Endocrinology Inc | 2 | $54 |
| Insulet Corporation | 3 | $53 |
| Cequr Corporation | 1 | $53 |
| Corcept Therapeutics | 2 | $39 |
| Ascensia Diabetes Care US Inc. | 1 | $31 |
| Rhythm Pharmaceuticals, Inc. | 1 | $29 |
| Acella Pharmaceuticals, LLC | 1 | $29 |
| Nevro Corp. | 1 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Sequel Med Tech, LLC | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tirosint$500
- Tirosint-SOL$500
How this compares
$331,150 in reported general payments places this provider in the 85th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 142 | $156,242 |
| JardianceEmpagliflozin | 101 | $100,719 |
| OzempicSemaglutide | 75 | $79,529 |
| ForteoTeriparatide | 18 | $78,978 |
| RybelsusSemaglutide | 26 | $31,572 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $29,339 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $19,345 |
| TrulicityDulaglutide | 18 | $18,696 |
| Novolog FlexpenInsulin Aspart | 24 | $6,141 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $5,324 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 26 | $4,967 |
| SynthroidLevothyroxine Sodium | 54 | $4,674 |
| Humalog Kwikpen U-100Insulin Lispro | 16 | $4,317 |
| Levemir FlexpenInsulin Detemir | 16 | $3,958 |
| Levothyroxine Sodium | 196 | $3,845 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Forteo, Trulicity | $142 | $253,916178 claims |
| Novo NordiskOzempic, Rybelsus | $657 | $111,102101 claims |
| Boehringer IngelheimJardiance | $20 | $100,719101 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $19 | $3,845196 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $29 | $1,11313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Round Rock
- Hien TranRound Rock$3.6M
- Kerem OzerRound Rock$2.3M
- Stephanie ShawRound Rock$936K
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
- Damaris VegaHouston$12.3M
- Mark KipnesSan Antonio$10.3M
- Amer Al KaradshehHouston$8.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.